Pre-treatment and on-treatment characteristics in patients with sustained virological response or virological relapse
| Characteristic | Sustained virological response(n = 139) | Virological relapse(n = 155) | p Value*(univariate) | p Value*(multivariate) |
|---|---|---|---|---|
| Patients were treated with peginterferon α-2a monotherapy or peginterferon α-2a plus lamivudine. ALT, alanine aminotransferase; HAI, Histological Activity Index; HBV, hepatitis B virus; LAM, lamivudine; PEG-IFNα-2a, peginterferon α-2a; ULN, upper limit of normal range. | ||||
| *Rates presented are actual rates for each subgroup. p Values are based on univariate or multivariate logistic regression models; †p values are from a separate logistic regression model performed on 254 patients with available baseline HAI scores and including all other characteristics listed above. | ||||
| Treatment | 0.77 | 0.54 | ||
| PEG-IFNα-2a | 47% | 46% | ||
| PEG-IFNα-2a+LAM | 53% | 54% | ||
| Age (years) | 0.002 | 0.024 | ||
| Mean±SD | 37.9±10.6 | 42.0±11.3 | ||
| Gender | ||||
| Male | 82% | 83% | 0.78 | 0.40 |
| Female | 18% | 17% | ||
| Body weight (kg) | 0.14 | 0.36 | ||
| Mean±SD | 68.7±12.7 | 70.9±13.0 | ||
| Baseline HAI score | 0.66† | 0.66† | ||
| Mean±SD | 8.6±3.5 | 8.8±3.5 | ||
| Baseline ALT | 0.12 | 0.23 | ||
| Mean±SD (IU/l) | 103±96 | 88±66 | ||
| >5×ULN | 19% | 15% | ||
| >2–5×ULN | 38% | 39% | ||
| ⩽2×ULN | 43% | 46% | ||
| ALT level at week 48 | 0.59 | 0.36 | ||
| >2×ULN | 15% | 12% | ||
| ⩽2×ULN | 85% | 88% | ||
| Peak ALT level weeks 0–48 (IU/l) | 0.28 | 0.26 | ||
| Mean±SD | 51±110 | 53±69 | ||
| Baseline HBV DNA (log10 copies/ml) | 0.15 | 0.01 | ||
| Mean±SD | 7.1±2.0 | 7.5±1.8 | ||
| HBV DNA at week 48 | 0.008 | 0.03 | ||
| ⩽400 copies/ml | 95% | 83% | ||
| >400–20 000 copies/ml | 5% | 18% | ||
| HBV genotype | <0.001 | 0.006 | ||
| A | 4% | 7% | ||
| B | 24% | 26% | ||
| C | 50% | 28% | ||
| D | 21% | 39% | ||